Douglas Baker
Analyst · Rosemarie Morbelli with G. Research. Please proceed with your question
Yes, happily. So Bioquell is a different business. It’s really, if you will, being integrated, let me define that word for a minute in this case into our life sciences business. So there will be some application of the Bioquell technology in healthcare or acute care specifically, which isn’t unusual for us. But predominantly, we view the Bioquell being targeted against the life sciences, i.e., pharma, cosmetic industries, et cetera. The life science approach here and, if you will, the acquisition model is fairly light touch initially from an integration standpoint, often our mantra. I mean, we stole it from somebody else, is make sure do no harm. We’ve got a great business with great technology, great competency in the team that we brought on. We want to understand how we most effectively leverage, if you will, the other parts of life sciences to advantage Bioquell and vice versa. That takes time. We have a thesis going in, but you need some experience to prove and learn how do you best do that. Long-term the Bioquell capabilities are always going to be somewhat unique, and so we’re always going to need, if you will, a unique center with people who are expert in specialist in that area. So we’re probably going to take more of an approach like we did with Anios, or we did with even KAY many years ago, which is utilize the asset, learn and understand the team, feed them with technology that can enhance them and learn from them how do you best, if you will, drive that business performance over time.